Aurobindo Pharma Ltd News

Why has Aurobindo Pharma stock gained 3% in trade today, November 25?

The collaboration and licencing agreement is set to span three to five years and focuses on the joint development of specific products within the respiratory therapeutic area, Aurobindo Pharma said

Oversold Alert: 5 stocks with RSI around 15; Colgate tests 20-year support

Asian Paints, Aurobindo Pharma, AIA Engineering, Delhivery and Colgate-Palmolive stocks were trading in oversold zone, the daily chart shows. Here are the key levels to track.

Aarti Ind, Auro Pharma, Trent stocks see short build-up; trading guide here

F&O data shows, on Friday Aarti Industries, Aurobindo Pharma and Trent saw a dip in share price alongside rise in open interest; thus implying short build-up at these counters.

Aurobindo Pharma subsidiary gets 10 observations from USFDA for API plant

Aurobindo Pharma on Monday said the US health regulator has issued 10 observations after inspecting the API facility of its subsidiary in Telangana. The US Food and Drug Administration (USFDA) inspected Unit-II, an active pharmaceutical ingredients (API) manufacturing facility of Apitoria Pharma, a wholly-owned subsidiary of the company, in Sangareddy district from September 23-27, 2024, the Hyderabad-based drug maker said in a regulatory filing. The inspection closed with 10 observations, it added. The observations are procedural in nature and will be responded to within the stipulated time, the drug maker stated. Shares of Aurobindo Pharma on Monday ended 3.16 per cent down at Rs 1,462 apiece on BSE.

Aurobindo Pharma share down 4% as arm gets 10 observations from USFDA

Aurobindo Pharma's subsidiary Apitoria Pharma has received 10 observations from the USFDA for its API manufacturing facility in Telangana

Aurobindo to acquire remaining 49% stake in GLS Pharma for Rs 22.5 crore

Aurobindo Pharma Ltd on Wednesday said it will acquire the balance 49 per cent stake in GLS Pharma Ltd for Rs 22.5 crore to make the latter a wholly-owned subsidiary. The company has entered into a binding agreement on September 18, 2024, with GLS Pharma Ltd and its promoters for acquisition of remaining 5,90,361 equity shares of Rs 10 each amounting to 49 per cent stake for a purchase consideration of Rs 22.5 crore. The shares are being acquired at a price of Rs 381.12 per share, Aurobindo Pharma said in a regulatory filing. "This acquisition is undertaken to hold the entire ownership of GLS by the company," it said, adding that the transaction is estimated to be completed before December 31, 2024. Aurobindo acquired a 51 per cent stake in GLS Pharma from promoters Suresh Pathak and his family members on June 17, 2022. GLS is engaged in oncology products, which include orals and injectables used in chemotherapy for solid malignancies, chemotherapy for hematological malignancies an

Aurobindo Pharma arm receives EIR from USFDA for Andhra Unit; stock down 2%

Aurobindo Pharma shares fell following the news that the US Food and Drug Administration has issued the Establishment Inspection Report (EIR) for the new injectable facility of Eugia Steriles

F&O cues: FIIs bullish on Nifty MidCap; JK Cement, Deepak Nitrite on radar

Derivatives market update for Friday, August 23: Analysts suggest Nifty options market reflects a bearish sentiment, with increased Call writing vs. Puts, as the index nears major hurdles.

Aurobindo Pharma stock tanks 6% after unit gets warning letter from USFDA

The drop in the share price came after the company announced that its' arm Eugia Pharma Specialties' Unit-III received a warning letter from United States Food and Drug Administration (USFDA).

TVS Motor, Aurobindo Pharma: Top picks by Chandan Taparia of Motilal Oswal

On the daily chart TVS Motor's price has broken out on the upside from an ascending triangle with higher-than-average buying volumes

Aurobindo Pharma hits lifetime high as analysts make bull case on growth

Shares of Aurobindo Pharmaceuticals soared as much as 4.96 per cent, hitting their all time high at Rs 1532.85 per share on the BSE in Tuesday's intraday trade

Aurobindo Pharma Q1FY25 results: Net profit jumps 61% to Rs 919 cr

Aurobindo Pharma on Saturday said its consolidated net profit increased 61 per cent year on year to Rs 919 crore in the first quarter ended June 2024, aided by strong sales across markets. The Hyderabad-based drug maker had reported a net profit of Rs 571 crore in the April-June quarter of last fiscal. Revenue from operations increased to Rs 7,567 crore in the June quarter as against Rs 6,851 crore in the year-ago period, the drug maker said in a statement. "We are pleased with our continued strong performance this quarter, with a significant top-line growth across all our business segments," Aurobindo Pharma Vice-Chairman and Managing Director K Nithyananda Reddy stated. The profitability was sustained by improved gross margins and operational efficiencies, while ramping up our recently commercialised plants, he added. "We are confident in our ability to achieve our growth targets for FY25," Reddy said.

Pharma shares rally; Suven, Granules, Ajanta, Jubilant surge over 5%

Q1 earnings cheer: Lupin, Zydus Lifesciences, Glenmark Pharmaceuticals, Aurobindo Pharma, Torrent Pharmaceuticals and Sun Pharmaceutical were up between 2 per cent and 3 per cent.

Aurobindo Pharma board approves share buyback plan worth Rs 750 cr

Aurobindo Pharma on Thursday said its board has approved a share buyback plan of up to Rs 750 crore. The company's board has approved the buyback of up to 51,36,986 shares representing up to 0.88 per cent of the total paid-up equity share capital, Aurobindo Pharma said in a regulatory filing. The company will buy the shares at Rs 1,460 apiece for an aggregate amount of up to Rs 750 crore, it added. The drug firm said July 30 has been fixed as the record date for the Rs 750-crore share buyback scheme through the tender offer route. At the end of June 30, the company promoters owned 51.8 per cent stake, while foreign institutional investors (FIIs) and mutual funds owned 16.73 per cent and 19.17 per cent respectively. Shares of Aurobindo Pharma were trading 2.83 per cent down at Rs 1,332.90 apiece on the BSE.

Aurobindo stock at new high, up 5% as board to consider buyback on July 18

In the past one year, the stock has zoomed 89 per cent, as compared to 21 per cent rally in the BSE Sensex.

Lupin, Eugia recall products from US over manufacturing issues: USFDA

Drugmaker Lupin and a unit of Aurobindo Pharma are recalling products from the American market due to manufacturing issues, according to the US health regulator. As per the latest Enforcement Report issued by the US Food and Drug Administration (USFDA), a US-based unit of Lupin is recalling a medication used to treat bacterial infections. Baltimore-based Lupin Pharmaceuticals Inc is recalling 3,552 bottles of Cefixime for Oral Suspension (USP 200 mg/5 mL) due to "failed content uniformity specifications". The affected lot has been produced at the company's Mandideep-based manufacturing plant in Madhya Pradesh. The company commenced the Class II nationwide (US) recall on May 30 this year. The US health regulator stated that New Jersey-based Eugia US LLC, a subsidiary of Aurobindo Pharma, is recalling 70,125 vials of Dexamethasone Sodium Phosphate injection USP. The company is recalling the affected lot due to "failed impurities/degradation specifications", USFDA said. Eugia com